AbCellera Biologics (ABCL) Profit After Tax (2020 - 2023)
Historic Profit After Tax for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$47.2 million.
- AbCellera Biologics' Profit After Tax fell 5772.92% to -$47.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 19235.36%. This contributed to the annual value of -$162.9 million for FY2024, which is 1124.26% down from last year.
- AbCellera Biologics' Profit After Tax amounted to -$47.2 million in Q4 2023, which was down 5772.92% from -$28.6 million recorded in Q3 2023.
- AbCellera Biologics' 5-year Profit After Tax high stood at $168.6 million for Q1 2022, and its period low was -$47.2 million during Q4 2023.
- In the last 4 years, AbCellera Biologics' Profit After Tax had a median value of -$2.5 million in 2020 and averaged $17.8 million.
- The largest annual percentage gain for AbCellera Biologics' Profit After Tax in the last 5 years was 570062.11% (2021), contrasted with its biggest fall of 69391.01% (2021).
- Quarter analysis of 4 years shows AbCellera Biologics' Profit After Tax stood at $117.0 million in 2020, then crashed by 48.76% to $59.9 million in 2021, then tumbled by 149.86% to -$29.9 million in 2022, then plummeted by 57.73% to -$47.2 million in 2023.
- Its last three reported values are -$47.2 million in Q4 2023, -$28.6 million for Q3 2023, and -$30.5 million during Q2 2023.